# Solaredge Technologies, Inc.: financial statements, quarterly

SEDG · Nasdaq · CIK 1419612 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sedg.md) · [Financials](/companies/sedg/financials.md) · [Filings](/companies/sedg/filings.md) · [Insiders](/companies/sedg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sedg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [725](/filings/0001178913-24-003529.md) | [316 d](/filings/0001178913-26-001595.md) | [204](/filings/0001178913-25-001662.md) | [265](/filings/0001178913-25-002690.md) | [235](/filings/0001178913-25-003678.md) | [196 d](/filings/0001178913-26-001595.md) | [219](/filings/0001178913-26-002432.md) | [289](/filings/0001178913-26-003854.md) | [340](/filings/0001178913-25-003678.md) | [335 d](/filings/0001178913-26-001595.md) | [311](/filings/0001178913-26-002432.md) | [346](/filings/0001178913-26-003854.md) |
| Cost of revenue | $m | [582](/filings/0001178913-24-003529.md) | [372 d](/filings/0001178913-26-001595.md) | [231](/filings/0001178913-25-001662.md) | [276](/filings/0001178913-25-002690.md) | [963](/filings/0001178913-25-003678.md) | [308 d](/filings/0001178913-26-001595.md) | [202](/filings/0001178913-26-002432.md) | [257](/filings/0001178913-26-003854.md) | [268](/filings/0001178913-25-003678.md) | [261 d](/filings/0001178913-26-001595.md) | [242](/filings/0001178913-26-002432.md) | [251](/filings/0001178913-26-003854.md) |
| Gross profit | $m | [143](/filings/0001178913-24-003529.md) | [(56.4) d](/filings/0001178913-26-001595.md) | [(26.2)](/filings/0001178913-25-001662.md) | [(11.0)](/filings/0001178913-25-002690.md) | [(728)](/filings/0001178913-25-003678.md) | [(112) d](/filings/0001178913-26-001595.md) | [17.5](/filings/0001178913-26-002432.md) | [32.1](/filings/0001178913-26-003854.md) | [72.1](/filings/0001178913-25-003678.md) | [74.5 d](/filings/0001178913-26-001595.md) | [68.3](/filings/0001178913-26-002432.md) | [95.2](/filings/0001178913-26-003854.md) |
| Research and development | $m | [80.1](/filings/0001178913-24-003529.md) | [75.0 d](/filings/0001178913-26-001595.md) | [75.4](/filings/0001178913-25-001662.md) | [69.3](/filings/0001178913-25-002690.md) | [70.4](/filings/0001178913-25-003678.md) | [62.2 d](/filings/0001178913-26-001595.md) | [62.0](/filings/0001178913-26-002432.md) | [53.4](/filings/0001178913-26-003854.md) | [54.1](/filings/0001178913-25-003678.md) | [51.7 d](/filings/0001178913-26-001595.md) | [50.2](/filings/0001178913-26-002432.md) | [52.8](/filings/0001178913-26-003854.md) |
| Operating income | $m | [(16.7)](/filings/0001178913-24-003529.md) | [(238) d](/filings/0001178913-26-001595.md) | [(174)](/filings/0001178913-25-001662.md) | [(160)](/filings/0001178913-25-002690.md) | [(1,111)](/filings/0001178913-25-003678.md) | [(264) d](/filings/0001178913-26-001595.md) | [(103)](/filings/0001178913-26-002432.md) | [(115)](/filings/0001178913-26-003854.md) | [(35.2)](/filings/0001178913-25-003678.md) | [(48.3) d](/filings/0001178913-26-001595.md) | [(55.0)](/filings/0001178913-26-002432.md) | [(16.0)](/filings/0001178913-26-003854.md) |
| Income tax | $m | [36.1](/filings/0001178913-24-003529.md) | [(53.2) d](/filings/0001178913-26-001595.md) | [(23.8)](/filings/0001178913-25-001662.md) | [(12.2)](/filings/0001178913-25-002690.md) | [121](/filings/0001178913-25-003678.md) | [11.0 d](/filings/0001178913-26-001595.md) | [5.7](/filings/0001178913-26-002432.md) | [5.7](/filings/0001178913-26-003854.md) | [2.6](/filings/0001178913-25-003678.md) | [(0.6) d](/filings/0001178913-26-001595.md) | [1.3](/filings/0001178913-26-002432.md) | [2.3](/filings/0001178913-26-003854.md) |
| Net income | $m | [(61.2)](/filings/0001178913-24-003529.md) | [(162) d](/filings/0001178913-26-001595.md) | [(157)](/filings/0001178913-25-003678.md) | [(131)](/filings/0001178913-25-003678.md) | [(1,231)](/filings/0001178913-25-003678.md) | [(287) d](/filings/0001178913-26-001595.md) | [(98.5)](/filings/0001178913-26-003854.md) | [(125)](/filings/0001178913-26-003854.md) | [(50.1)](/filings/0001178913-25-003678.md) | [(132) d](/filings/0001178913-26-001595.md) | [(57.4)](/filings/0001178913-26-003854.md) | [(30.8)](/filings/0001178913-26-003854.md) |
| Diluted EPS | $ per share | [(1.08)](/filings/0001178913-24-003529.md) | not reported | [(2.75)](/filings/0001178913-25-001662.md) | [(2.31)](/filings/0001178913-25-002690.md) | [(21.58)](/filings/0001178913-25-003678.md) | not reported | [(1.70)](/filings/0001178913-26-002432.md) | [(2.13)](/filings/0001178913-26-003854.md) | [(0.84)](/filings/0001178913-25-003678.md) | not reported | [(0.95)](/filings/0001178913-26-002432.md) | [(0.50)](/filings/0001178913-26-003854.md) |
| Basic EPS | $ per share | [(1.08)](/filings/0001178913-24-003529.md) | not reported | [(2.75)](/filings/0001178913-25-001662.md) | [(2.31)](/filings/0001178913-25-002690.md) | [(21.58)](/filings/0001178913-25-003678.md) | not reported | [(1.70)](/filings/0001178913-26-002432.md) | [(2.13)](/filings/0001178913-26-003854.md) | [(0.84)](/filings/0001178913-25-003678.md) | not reported | [(0.95)](/filings/0001178913-26-002432.md) | [(0.50)](/filings/0001178913-26-003854.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [551](/filings/0001178913-23-003538.md) | [338](/filings/0001178913-26-001595.md) | [214](/filings/0001178913-25-001662.md) | [259](/filings/0001178913-25-002690.md) | [304](/filings/0001178913-25-003678.md) | [275](/filings/0001178913-26-001595.md) | [401](/filings/0001178913-26-002432.md) | [545](/filings/0001178913-26-003854.md) | [440](/filings/0001178913-25-003678.md) | [455](/filings/0001178913-26-003854.md) | [512](/filings/0001178913-26-002432.md) | [527](/filings/0001178913-26-003854.md) |
| Current assets | $m | [3,363](/filings/0001178913-23-003538.md) | [3,304](/filings/0001178913-25-000605.md) | [2,989](/filings/0001178913-24-001670.md) | [2,893](/filings/0001178913-24-002470.md) | [2,118](/filings/0001178913-24-003529.md) | [2,051](/filings/0001178913-26-001595.md) | [1,990](/filings/0001178913-25-001662.md) | [1,972](/filings/0001178913-25-002690.md) | [1,768](/filings/0001178913-25-003678.md) | [1,740](/filings/0001178913-26-003854.md) | [1,817](/filings/0001178913-26-002432.md) | [1,868](/filings/0001178913-26-003854.md) |
| Total assets | $m | [4,651](/filings/0001178913-23-003538.md) | [4,588](/filings/0001178913-25-000605.md) | [4,167](/filings/0001178913-24-001670.md) | [3,948](/filings/0001178913-24-002470.md) | [2,816](/filings/0001178913-24-003529.md) | [2,646](/filings/0001178913-26-001595.md) | [2,525](/filings/0001178913-25-001662.md) | [2,490](/filings/0001178913-25-002690.md) | [2,232](/filings/0001178913-25-003678.md) | [2,182](/filings/0001178913-26-003854.md) | [2,261](/filings/0001178913-26-002432.md) | [2,304](/filings/0001178913-26-003854.md) |
| Current liabilities | $m | [877](/filings/0001178913-23-003538.md) | [893](/filings/0001178913-25-000605.md) | [659](/filings/0001178913-24-001670.md) | [567](/filings/0001178913-24-002470.md) | [904](/filings/0001178913-24-003529.md) | [1,057](/filings/0001178913-26-001595.md) | [974](/filings/0001178913-25-001662.md) | [1,017](/filings/0001178913-25-002690.md) | [775](/filings/0001178913-25-003678.md) | [803](/filings/0001178913-26-003854.md) | [897](/filings/0001178913-26-002432.md) | [920](/filings/0001178913-26-003854.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,490](/filings/0001178913-24-003529.md) | [2,412](/filings/0001178913-26-001595.md) | [2,241](/filings/0001178913-25-003678.md) | [2,106](/filings/0001178913-25-003678.md) | [931](/filings/0001178913-25-003678.md) | [658](/filings/0001178913-26-003854.md) | [594](/filings/0001178913-26-003854.md) | [513](/filings/0001178913-26-003854.md) | [480](/filings/0001178913-25-003678.md) | [427](/filings/0001178913-26-003854.md) | [411](/filings/0001178913-26-003854.md) | [412](/filings/0001178913-26-003854.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [40.6 d](/filings/0001178913-24-003529.md) | [(140) d](/filings/0001178913-26-001595.md) | [(217)](/filings/0001178913-25-001662.md) | [(44.8) d](/filings/0001178913-25-002690.md) | [(89.3) d](/filings/0001178913-25-003678.md) | [37.8 d](/filings/0001178913-26-001595.md) | [33.8](/filings/0001178913-26-002432.md) | [(7.8) d](/filings/0001178913-26-003854.md) | [25.6 d](/filings/0001178913-25-003678.md) | [52.6 d](/filings/0001178913-26-001595.md) | [24.4](/filings/0001178913-26-002432.md) | [11.4 d](/filings/0001178913-26-003854.md) |
| Capital expenditure | $m | [45.9 d](/filings/0001178913-24-003529.md) | [40.5 d](/filings/0001178913-26-001595.md) | [26.3](/filings/0001178913-25-001662.md) | [22.2 d](/filings/0001178913-25-002690.md) | [47.4 d](/filings/0001178913-25-003678.md) | [12.3 d](/filings/0001178913-26-001595.md) | [10.1](/filings/0001178913-26-002432.md) | [1.3 d](/filings/0001178913-26-003854.md) | [2.8 d](/filings/0001178913-25-003678.md) | [9.3 d](/filings/0001178913-26-001595.md) | [3.7](/filings/0001178913-26-002432.md) | [8.3 d](/filings/0001178913-26-003854.md) |
| Share repurchases | $m | [0.0 d](/filings/0001178913-24-003529.md) | [0.0 d](/filings/0001178913-26-001595.md) | [33.2](/filings/0001178913-25-001662.md) | [16.8 d](/filings/0001178913-25-002690.md) | [0.3 d](/filings/0001178913-25-003678.md) | [(0.1) d](/filings/0001178913-26-001595.md) | [0.0](/filings/0001178913-25-001662.md) | [0.0 d](/filings/0001178913-25-002690.md) | [0.0 d](/filings/0001178913-25-003678.md) | [0.0 d](/filings/0001178913-26-001595.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [58.7](/filings/0001178913-23-003538.md) | [59.2](/filings/0001178913-24-001670.md) | [59.2](/filings/0001178913-24-002470.md) | [56.7](/filings/0001178913-24-003529.md) | [57.1](/filings/0001178913-25-001662.md) | [56.7](/filings/0001178913-25-002690.md) | [57.0](/filings/0001178913-25-003678.md) | [58.1](/filings/0001178913-26-002432.md) | [58.6](/filings/0001178913-26-003854.md) | [59.3](/filings/0001178913-25-003678.md) | [60.5](/filings/0001178913-26-002432.md) | [61.0](/filings/0001178913-26-003854.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,525,748 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001178913-26-003854.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.